Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 31Nivolumab 11Ipilimumab 6spartalizumab 5cemiplimab 5atezolizumab 5Gemcitabine 4Docetaxel 4durvalumab 3budigalimab 3avelumab 3Oxaliplatin 3Leucovorin 3Irinotecan 3Immune Checkpoint Inhibitors 3Fluorouracil 3Cyclophosphamide 3Cetuximab 3Carboplatin 3130-nm albumin-bound paclitaxel 3obinutuzumab 2lenvatinib 2fludarabine 2epacadostat 2X-Rays 2Paclitaxel 2Immunoglobulin G 2Cisplatin 2Capecitabine 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Antibodies × Head & Neck × Clear all
NCT06451497 2026-04-02

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Zumutor Biologics Inc.

Phase 1 Recruiting
100 enrolled
BreastGastrointestinalGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡